Moderna says a study in kids 6 to 11 found two doses of the company’s COVID-19 vaccine given 28 days apart produced a strong antibody response.
The study, conducted in collaboration with the National Institutes of Health, used shots containing a 50 microgram dose of the vaccine, half the dose of the Moderna shots authorized for adults. More than 4,700 children ages 5 to 11 took part in the study.
The release of the data comes a day before a panel of advisers to the Food and Drug Administration will review use of the Pfizer-BioNTech COVID-19 vaccine in children 5 to 11 years of age.
Read the full article.
Breaking News: Moderna’s Covid vaccine is safe and produces a powerful immune response in children aged 6 through 11, the company said.
The results come one day before an FDA panel is set to review data for Pfizer’s vaccine in children 5 through 11.https://t.co/VPeip7qfqI
— The New York Times (@nytimes) October 25, 2021